N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis.

Ras genes can be altered by point mutations at critical portions of their coding regions to acquire transforming ability in vitro. These point mutations have been detected in a variety of human malignancies. However, their relevance for the clinical and biologic behavior of the subgroups of patients exhibiting these mutations in unclear. We analyzed 100 patients with childhood acute lymphocytic leukemias (ALLs) for point mutations of exons 1 and 2 of all three ras genes (H-ras, K-ras, and N-ras) by polymerase chain reaction and a combination of oligonucleotide hybridization and direct DNA sequencing. A 6% incidence of N-ras gene mutations was detected, all of which occurred at different nucleotides of codons 12 or 13 of N-ras. When correlating presence of ras mutations with the clinical and biologic features and the clinical outcome of these cases, a significantly higher risk for hematologic relapse (P = .01) and a trend toward a lower rate of complete remission (P = .07) was noted. The two groups did not differ in any of the known high-risk factors of ALL. These results suggest that presence of an N-ras mutation in children with ALL may be an independent predictor for worse clinical outcome and therefore may have therapeutic implications; further studies to confirm these findings are required because of the small number of patients with N-ras mutations.

[1]  R. Kumar,et al.  Oncogene detection at the single cell level. , 1988, Oncogene.

[2]  F. Behm,et al.  Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity. , 1988, Blood.

[3]  A. Levinson,et al.  A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene , 1988, Nature.

[4]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[5]  R. Saiki,et al.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Bartram,et al.  RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[8]  M. J. van de Vijver,et al.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene , 1987, Molecular and cellular biology.

[9]  M. Stoneking,et al.  Length mutations in human mitochondrial DNA: direct sequencing of enzymatically amplified DNA. , 1987, Nucleic acids research.

[10]  Henry A. Erlich,et al.  Analysis of enzymatically amplified β-globin and HLA-DQα DNA with allele-specific oligonucleotide probes , 1986, Nature.

[11]  C. Marshall,et al.  Transformation and stimulation of DNA synthesis in NIH‐3T3 cells are a titratable function of normal p21N‐ras expression. , 1986, The EMBO journal.

[12]  S. Rodenhuis,et al.  Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood , 1986 .

[13]  S. Srivastava,et al.  High frequency of N-ras activation in acute myelogenous leukemia , 1986 .

[14]  R. Atchison,et al.  Regulation of expression of the human interferon gamma gene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Stass,et al.  Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance , 1985 .

[16]  K. C. Reed,et al.  Rapid transfer of DNA from agarose gels to nylon membranes. , 1985, Nucleic acids research.

[17]  C. Marshall,et al.  Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia , 1985, Nature.

[18]  J. Bos,et al.  Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization. , 1984, Nucleic acids research.

[19]  C. Cooper,et al.  An activated rasN gene: detected in late but not early passage human PA1 teratocarcinoma cells. , 1984, Science.

[20]  M. Barbacid,et al.  Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. , 1984, Science.

[21]  Robert A. Weinberg,et al.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.

[22]  S. Aaronson,et al.  Transforming genes of human hematopoietic tumors: frequent detection of ras-related oncogenes whose activation appears to be independent of tumor phenotype. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Eugenio Santos,et al.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene , 1982, Nature.

[24]  Tom Maniatis,et al.  Transformation of mammalian cells with genes from procaryotes and eucaryotes , 1979, Cell.

[25]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[27]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[29]  William E. Grizzle,et al.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis , 1987, Nature.

[30]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[31]  J. Jiricny,et al.  Amino acid substitution at position 13 of the N-ras gene in a non-Hodgkin's lymphoma patient. , 1987, Haematology and blood transfusion.

[32]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.

[33]  S. Rodenhuis,et al.  Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. , 1986, Blood.

[34]  S. Srivastava,et al.  High frequency of N-ras activation in acute myelogenous leukemia. , 1986, Blood.

[35]  J. Bos,et al.  A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides. , 1986, Gene.